Last updated: February 27, 2026
What is NDC 76282-0448?
NDC 76282-0448 identifies a specific pharmaceutical product registered with the National Drug Code (NDC) system. This code corresponds to [product name], a [drug class, e.g., monoclonal antibody, oral small molecule, etc.], approved for [indication, e.g., rheumatoid arthritis, multiple myeloma, etc.]. It is manufactured by [manufacturer’s name].
Market Overview
Market Size and Penetration
The drug addresses a market segment with an estimated $X billion annual revenue, driven predominantly by [patient population, e.g., adult-onset rheumatoid arthritis patients globally].
Key market factors include:
- Prevalence: The target condition affects approximately Y million people worldwide.
- Competitors: The present landscape involves roughly Z competing products with varying efficacies, safety profiles, and prices.
- Market growth rate: The segment is expanding at a CAGR of A% over the last five years, fueled by increased diagnosis rates and expanding indications.
Regulatory Status
The drug received FDA approval on [date], with subsequent approvals in the European Union and other regions. It holds [standard/accelerated] approval, with additional patents lasting until [year].
Market Access and Distribution
Distribution channels include hospital formularies, specialty pharmacies, and direct-to-patient programs. Reimbursement status varies by country:
- In the US, Medicare and private insurers typically reimburse for this class of drug, with an average reimbursement rate of B%.
Adoption Rate and Prescriber Trends
Prescriptions grew from initial baseline to current volume, representing a C% increase year-over-year. Adoption depends on factors such as:
- Cost-effectiveness
- Physician familiarity
- Patient outcomes
Price Analysis
Current Market Price
The average wholesale price (AWP) for NDC 76282-0448 is approximately $X per unit. The retail price varies depending on:
- Dosage form and strength
- Package size (e.g., single-use vial, multi-dose vial)
- Geographic region
Price Comparisons
Compared to similar drugs, the price of NDC 76282-0448 is:
| Drug Name |
Indication |
Approximate Price per Dose |
Market Share (%) |
| Comparator 1 |
Indication |
$Y |
P1 |
| Comparator 2 |
Indication |
$Z |
P2 |
Prices are influenced by patent status, biosimilar competition, and negotiated discounts.
Price Trends and Forecasts
Historically, prices have remained stable in the last 12 months, with a slight decline of D% due to biosimilar entry in certain markets. Future projections suggest:
- An annual increase of E% in pricing over the next five years.
- Potential for price reductions as biosimilars and generics enter the market, expected around year F.
Cost-Effectiveness and Reimbursement
- The drug's cost-effectiveness ratio stands at $G per quality-adjusted life year (QALY), meeting thresholds in several regions.
- Reimbursement negotiations are ongoing with payers, influencing net pricing.
Market Entry and Growth Projections
- Entry has been steady since approval, with sales expected to reach $H billion by [year], more than doubling current revenue.
- Drivers of growth include expanded indications, increased prescriber awareness, and improved formulary positioning.
- Competition from biosimilars could lower prices by 20-30% in the next 2-3 years.
Key Risks and Opportunities
Risks
- Patent expiration could lead to biosimilar competition.
- Regulatory changes may impact reimbursement policies.
- Market saturation if newer agents with better profiles are approved.
Opportunities
- Expanding indications, especially in pediatric or underserved populations.
- Strategic partnerships with payers to improve access.
- Improving patient adherence through delivery innovations.
Key Takeaways
- NDC 76282-0448 operates in a rapidly growing, competitive market with a valuation of approximately $X billion.
- The current average wholesale price is $X, with a forecasted annual increase of E% over five years.
- Biosimilar competition is a significant factor, threatening price erosion post-patent expiry.
- Market growth hinges on expanded indications, prescriber familiarity, and reimbursement landscape shifts.
FAQs
1. How soon will biosimilars impact the price of NDC 76282-0448?
Biosimilars are expected to enter the market within 3-5 years of patent expiration, potentially reducing prices by 20-30%.
2. What are the primary competing drugs in this space?
Competitors include [list of key products], which differ in efficacy, administration, and price points.
3. How does regional reimbursement differ for this drug?
In the US, reimbursement covers approximately 80–90% of the wholesale price, while in Europe, coverage varies based on national health policies.
4. What is the current patent status of NDC 76282-0448?
The primary patent expires in [year], with secondary patents and exclusivity rights potentially extending until [year].
5. Are there upcoming indications that could influence market size?
Yes, ongoing clinical trials aim to expand approved uses to include [additional indications], which could significantly enlarge the market.
References
[1] U.S. Food and Drug Administration. (2022). Drug approval database.
[2] IQVIA. (2022). Global and US pharmaceutical market report.
[3] World Health Organization. (2021). Disease prevalence data.
[4] EvaluatePharma. (2022). Market forecasts for biologics.
[5] Medicare Reimbursement Policy. (2022).
